Pathological examination of radical prostatectomy specimens in men with very low risk disease at biopsy reveals distinct zonal distribution of cancer in black American men.

[1]  Shyam Natarajan,et al.  Value of targeted prostate biopsy using magnetic resonance-ultrasound fusion in men with prior negative biopsy and elevated prostate-specific antigen. , 2014, European urology.

[2]  Kazutaka Saito,et al.  High diagnostic ability of multiparametric magnetic resonance imaging to detect anterior prostate cancer missed by transrectal 12-core biopsy. , 2013, The Journal of urology.

[3]  A. Partin,et al.  African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them? , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  L. Marks.  Improving risk stratification in patients with prostate cancer managed by active surveillance: a nomogram predicting the risk of biopsy progression. , 2013 .

[5]  A. Partin,et al.  Increased incidence of pathologically nonorgan confined prostate cancer in African-American men eligible for active surveillance. , 2013, Urology.

[6]  J. McKiernan,et al.  Pathological outcome and biochemical recurrence‐free survival after radical prostatectomy in African‐American, Afro‐Caribbean (Jamaican) and Caucasian‐American men: an international comparison , 2013, BJU international.

[7]  Aliccia Bollig-Fischer,et al.  Genes Associated with Prostate Cancer Are Differentially Expressed in African American and European American Men , 2013, Cancer Epidemiology, Biomarkers & Prevention.

[8]  M. Cooperberg,et al.  Active surveillance for prostate cancer: a systematic review of the literature. , 2012, European urology.

[9]  J. McKiernan,et al.  Role of immediate confirmatory prostate biopsy to ensure accurate eligibility for active surveillance. , 2012, Urology.

[10]  Michael N. Ferrandino,et al.  Race is associated with discontinuation of active surveillance of low-risk prostate cancer: Results from the Duke Prostate Center , 2012, Prostate Cancer and Prostatic Diseases.

[11]  M. Soloway,et al.  Clinical and demographic characteristics associated with prostate cancer progression in patients on active surveillance. , 2012, The Journal of urology.

[12]  R. Stock,et al.  Impact of race on biochemical disease recurrence after prostate brachytherapy , 2011, Cancer.

[13]  M. Cooperberg,et al.  The CAPRA‐S score , 2011, Cancer.

[14]  S. Bigler,et al.  A Retrospective Study on Pathologic Features and Racial Disparities in Prostate Cancer , 2011, Prostate cancer.

[15]  Krishna R. Kalari,et al.  Detecting gene-gene interactions in prostate disease in African American men , 2011, Infectious Agents and Cancer.

[16]  J. Epstein,et al.  Initial High-grade Prostatic Intraepithelial Neoplasia With Carcinoma on Subsequent Prostate Needle Biopsy: Findings at Radical Prostatectomy , 2011, The American journal of surgical pathology.

[17]  M. Rubin,et al.  TMPRSS2–ERG gene fusion prevalence and class are significantly different in prostate cancer of caucasian, african‐american and japanese patients , 2011, The Prostate.

[18]  A. Partin,et al.  Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  W. Sakr,et al.  Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in black than in white American men, and influences racial progression and mortality disparity. , 2010, The Journal of urology.

[20]  A. Evans,et al.  ‘Prostatic evasive anterior tumours’: the role of magnetic resonance imaging , 2010, BJU international.

[21]  B. Trock,et al.  Delayed versus immediate surgical intervention and prostate cancer outcome. , 2006, Journal of the National Cancer Institute.

[22]  L. Egevad,et al.  The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma , 2005, The American journal of surgical pathology.

[23]  Alan W Partin,et al.  Characteristics of insignificant clinical T1c prostate tumors , 2004, Cancer.

[24]  T. Stamey,et al.  Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens. , 2002, Urology.

[25]  M. Banerjee,et al.  Racial differences and prognostic significance of tumor location in radical prostatectomy specimens , 1998, The Prostate.

[26]  D. Johnston,et al.  Prostate specific antigen and pathological features of prostate cancer in black and white patients: a comparative study based on radical prostatectomy specimens. , 1998, The Journal of urology.

[27]  J. Moul,et al.  Black race is an adverse prognostic factor for prostate cancer recurrence following radical prostatectomy in an equal access health care setting. , 1996, The Journal of urology.

[28]  F. Mostofi,et al.  Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men. , 1995, JAMA.

[29]  P. Walsh,et al.  Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. , 1994, JAMA.

[30]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[31]  G. Chornokur,et al.  The Prostate 71 : 985 ^ 997 ( 2011 ) Disparities at Presentation , Diagnosis , Treatment , and SurvivalinAfricanAmericanMen , Affectedby ProstateCancer , 2011 .

[32]  Anthony D'Amico,et al.  Prostate cancer. Clinical practice guidelines in oncology. , 2007, Journal of the National Comprehensive Cancer Network : JNCCN.

[33]  A. Mckenzie,et al.  The role of magnetic resonance imaging. When to use it and what to look for. , 1997, Acta orthopaedica Scandinavica. Supplementum.